TRACON Pharmaceuticals Company Profile (NASDAQ:TCON)

About TRACON Pharmaceuticals

TRACON Pharmaceuticals logoTRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TCON
  • CUSIP:
Key Metrics:
  • Previous Close: $3.90
  • 50 Day Moving Average: $4.69
  • 200 Day Moving Average: $5.55
  • 52-Week Range: $3.60 - $7.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.73
  • P/E Growth: 0.00
  • Market Cap: $50.95M
  • Outstanding Shares: 13,065,000
  • Beta: 2.77
Profitability:
  • Net Margins: -750.91%
  • Return on Equity: -137.76%
  • Return on Assets: -72.55%
Debt:
  • Debt-to-Equity Ratio: 0.27%
  • Current Ratio: 2.77%
  • Quick Ratio: 2.77%
Additional Links:
Companies Related to TRACON Pharmaceuticals:

Analyst Ratings

Consensus Ratings for TRACON Pharmaceuticals (NASDAQ:TCON) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $13.00 (233.33% upside)

Analysts' Ratings History for TRACON Pharmaceuticals (NASDAQ:TCON)
Show:
DateFirmActionRatingPrice TargetDetails
1/5/2017Stifel NicolausReiterated RatingBuy$14.00View Rating Details
1/3/2017Wells Fargo & CoDowngradeOutperform -> Market PerformView Rating Details
12/21/2016Jefferies Group LLCInitiated CoverageBuy$10.00View Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$15.00View Rating Details
2/1/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperformView Rating Details
10/8/2015Roth CapitalReiterated RatingBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for TRACON Pharmaceuticals (NASDAQ:TCON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017        
8/10/2016Q2($0.62)($0.68)ViewListenView Earnings Details
5/11/2016Q1($0.70)($0.54)ViewListenView Earnings Details
2/18/2016Q4($0.62)($0.91)ViewListenView Earnings Details
11/3/2015Q3($0.51)($0.53)ViewListenView Earnings Details
8/5/2015Q215($0.42)($0.24)$4.20 millionViewListenView Earnings Details
5/13/2015Q1($0.37)($0.50)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TRACON Pharmaceuticals (NASDAQ:TCON)
Current Year EPS Consensus Estimate: $-2.23 EPS
Next Year EPS Consensus Estimate: $-2.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.56)($0.56)($0.56)
Q2 20162($0.70)($0.46)($0.58)
Q3 20162($0.75)($0.48)($0.62)
Q4 20163($0.85)($0.50)($0.62)
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.52)($0.52)($0.52)
Q3 20171($0.44)($0.44)($0.44)
Q4 20171($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TRACON Pharmaceuticals (NASDAQ:TCON)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for TRACON Pharmaceuticals (NASDAQ:TCON)
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 24.03%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Peter W SonsiniMajor ShareholderBuy869,565$5.75$4,999,998.75View SEC Filing  
6/3/2016Ronald L ShazerInsiderSell1,003$7.48$7,502.44View SEC Filing  
10/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell1,500$9.90$14,850.00View SEC Filing  
10/15/2015Jafco Super V3 Investment LimiMajor ShareholderSell5,300$10.16$53,848.00View SEC Filing  
10/13/2015Jafco Super V3 Investment Limimajor shareholderSell3,168$10.01$31,711.68View SEC Filing  
10/9/2015Jafco Super V3 Investment Limimajor shareholderSell1,448$10.01$14,494.48View SEC Filing  
10/8/2015Jafco Super V3 Investment Limimajor shareholderSell21,920$10.10$221,392.00View SEC Filing  
10/5/2015Jafco Super V3 Investment Limimajor shareholderSell15,100$10.08$152,208.00View SEC Filing  
9/25/2015Jafco Super V3 Investment LimiMajor ShareholderSell7,600$12.13$92,188.00View SEC Filing  
9/24/2015Jafco Super V3 Investment Limimajor shareholderSell22,303$12.99$289,715.97View SEC Filing  
9/22/2015Jafco Super V3 Investment Limimajor shareholderSell39,426$14.02$552,752.52View SEC Filing  
9/21/2015Jafco Super V3 Investment Limimajor shareholderSell18,200$14.48$263,536.00View SEC Filing  
9/18/2015Charles TheuerCEOSell10,000$17.34$173,400.00View SEC Filing  
9/18/2015H Casey LoganinsiderSell5,000$17.34$86,700.00View SEC Filing  
9/17/2015Jafco Super V3 Investment Limimajor shareholderSell42,344$11.78$498,812.32View SEC Filing  
9/14/2015Jafco Super V3 Investment Limimajor shareholderSell60,038$11.78$707,247.64View SEC Filing  
9/10/2015Charles TheuerCEOSell3,516$12.00$42,192.00View SEC Filing  
9/9/2015Jafco Super V3 Investment Limimajor shareholderSell12,000$10.71$128,520.00View SEC Filing  
9/8/2015Jafco Super V3 Investment Limimajor shareholderSell5,700$10.47$59,679.00View SEC Filing  
9/4/2015Jafco Super V3 Investment Limimajor shareholderSell6,600$10.48$69,168.00View SEC Filing  
9/3/2015Jafco Super V3 Investment Limimajor shareholderSell15,300$10.51$160,803.00View SEC Filing  
9/1/2015Jafco Super V3 Investment Limimajor shareholderSell14,000$10.42$145,880.00View SEC Filing  
8/24/2015Jafco Super V3 Investment LimiMajor ShareholderSell3,000$11.00$33,000.00View SEC Filing  
8/20/2015Jafco Super V3 Investment Limimajor shareholderSell10,683$11.36$121,358.88View SEC Filing  
8/18/2015Jafco Super V3 Investment LimiMajor ShareholderSell11,174$11.71$130,847.54View SEC Filing  
8/13/2015Jafco Super V3 Investment LimiMajor ShareholderSell9,361$11.60$108,587.60View SEC Filing  
2/4/2015M James BarrettMajor ShareholderBuy500,000$10.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for TRACON Pharmaceuticals (NASDAQ:TCON)
DateHeadline
finance.yahoo.com logoTRACON to Report Fourth Quarter and Full Year 2016 Company Highlights and Financial Results on February 28, 2017 (NASDAQ:TCON)
finance.yahoo.com - February 21 at 4:47 PM
finance.yahoo.com logoTRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma (NASDAQ:TCON)
finance.yahoo.com - February 16 at 7:59 PM
investopedia.com logoTracon Tanks on Brain Cancer Drug Failure (TCON) - Investopedia (NASDAQ:TCON)
www.investopedia.com - February 13 at 8:39 PM
investopedia.com logoTracon Pharma Tanks on Brain Cancer Drug Failure (NASDAQ:TCON)
www.investopedia.com - February 13 at 3:38 PM
nasdaq.com logoHealth Care Sector Update for 02/10/2017: TCON,IMMU,SGEN,BSTG - Nasdaq (NASDAQ:TCON)
www.nasdaq.com - February 12 at 1:18 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:TCON)
biz.yahoo.com - February 11 at 8:17 PM
nasdaq.com logoMid-Morning Market Update: Markets Open Higher; NVIDIA Beats Q4 Views (NASDAQ:TCON)
www.nasdaq.com - February 11 at 5:05 AM
marketexclusive.com logoTRACON Pharmaceuticals Inc (NASDAQ:TCON) Can Still Recover, Just Not With GBM (NASDAQ:TCON)
marketexclusive.com - February 11 at 5:05 AM
us.rd.yahoo.com logoTRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma (NASDAQ:TCON)
us.rd.yahoo.com - February 10 at 5:57 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin (NASDAQ:TCON)
biz.yahoo.com - February 9 at 6:04 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:TCON)
biz.yahoo.com - February 9 at 6:04 AM
News IconTechnical Trading: Focus on Shares of Tracon Pharmaceuticals Inc. (TCON) - Sherwood Daily (NASDAQ:TCON)
sherwooddaily.com - February 3 at 6:09 AM
News IconInside Track: Trading Focus on Shares of Tracon Pharmaceuticals Inc. (TCON) - Sherwood Daily (NASDAQ:TCON)
sherwooddaily.com - February 2 at 5:48 AM
News IconShares in Focus: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - The Tribune (NASDAQ:TCON)
lakecitytribune.com - February 1 at 6:50 AM
News IconStock Momentum in Focus on Shares of Tracon Pharmaceuticals Inc. (TCON) - Sherwood Daily (NASDAQ:TCON)
sherwooddaily.com - January 28 at 6:53 AM
News IconEarnings in Full Force, Analysts Take Aim at TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Wall Street Beacon (NASDAQ:TCON)
wsbeacon.com - January 28 at 6:53 AM
News IconTrading Views: Checking the Numbers for Tracon Pharmaceuticals Inc. (TCON) - Sherwood Daily (NASDAQ:TCON)
sherwooddaily.com - January 26 at 6:14 AM
News IconTechnical Toolbox: Investor Focus on Tracon Pharmaceuticals Inc. (TCON) - Sherwood Daily (NASDAQ:TCON)
sherwooddaily.com - January 25 at 6:25 AM
News IconChecking on CCI, MA, RSI and ADX for Tracon Pharmaceuticals Inc. (TCON) - Sherwood Daily (NASDAQ:TCON)
sherwooddaily.com - January 23 at 8:10 AM
News IconTRACON Pharmaceuticals Inc TCON Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:TCON)
www.bioportfolio.com - January 18 at 4:16 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Wall Street Beacon (NASDAQ:TCON)
wsbeacon.com - January 15 at 1:15 AM
News IconWill The Needle Move For TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:TCON)
wsbeacon.com - January 13 at 4:36 PM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos (NASDAQ:TCON)
biz.yahoo.com - January 10 at 1:19 AM
seekingalpha.com logoTracon Pharmaceuticals: ~$5 Biotech Stock With Plenty Of Catalysts In 2017 (NASDAQ:TCON)
seekingalpha.com - January 7 at 3:51 AM
marketexclusive.com logoAnalyst Activity – Stifel Nicolaus Reiterates Buy on TRACON Pharmaceuticals (NASDAQ:TCON) - Market Exclusive (NASDAQ:TCON)
marketexclusive.com - January 6 at 6:02 AM
marketexclusive.com logoAnalyst Downgrades – TRACON Pharmaceuticals (NASDAQ:TCON) Stock Gets Downgraded By Wells Fargo & Company from Market Perform to (NASDAQ:TCON)
marketexclusive.com - January 4 at 6:04 AM
us.rd.yahoo.com logo8:05 am Tracon Pharmaceuticals receives special protocol assessment agreement from FDA for phase 3 clinical trial of TRC105 in Angiosarcoma (NASDAQ:TCON)
us.rd.yahoo.com - January 3 at 9:21 AM
publicnow.com logoTRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement from FDA for Phase 3 Clinical Trial of TRC105 in Angiosarcoma (NASDAQ:TCON)
www.publicnow.com - January 3 at 9:21 AM
News IconTo Buy Or Sell TRACON Pharmaceuticals, Inc. (TCON) On Latest Analyst Consensus (NASDAQ:TCON)
viveremilano.biz - December 23 at 8:21 PM
investornewswire.com logoTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:TCON)
www.investornewswire.com - December 23 at 1:19 AM
capitalcube.com logoETFs with exposure to TRACON Pharmaceuticals, Inc. : December 22, 2016 (NASDAQ:TCON)
www.capitalcube.com - December 23 at 1:19 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and (NASDAQ:TCON)
biz.yahoo.com - December 22 at 3:58 AM
finance.yahoo.com logoCoverage initiated on Tracon Pharmaceuticals by Jefferies (NASDAQ:TCON)
finance.yahoo.com - December 22 at 3:58 AM
News IconThis Weeks Target Prices For TRACON Pharmaceuticals, Inc. (TCON) - NewsDen (NASDAQ:TCON)
newsden.net - December 19 at 10:50 AM
News IconCCI Level Check for Tracon Pharmaceuticals Inc. (TCON) - Yankee Analysts (NASDAQ:TCON)
yankeeanalysts.com - December 16 at 5:29 AM
4-traders.com logoTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:TCON)
www.4-traders.com - December 14 at 3:25 PM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and (NASDAQ:TCON)
biz.yahoo.com - December 14 at 5:46 AM
capitalcube.com logoETFs with exposure to TRACON Pharmaceuticals, Inc. : December 9, 2016 (NASDAQ:TCON)
www.capitalcube.com - December 9 at 8:03 PM
News IconTraders are Taking a Closer Look at These Shares: Tracon Pharmaceuticals Inc. (TCON) - Yankee Analysts (NASDAQ:TCON)
yankeeanalysts.com - December 7 at 8:13 AM
News IconInvestor Arena: Keeping an Eye on Tracon Pharmaceuticals Inc. (TCON) - StockTalk Daily (NASDAQ:TCON)
stocktalkdaily.com - December 4 at 8:38 AM
News IconTraders are Following Technical Levels for Tracon Pharmaceuticals Inc. (TCON) - Yankee Analysts (NASDAQ:TCON)
yankeeanalysts.com - December 2 at 8:20 PM
investornewswire.com logoBuy Calls Of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) At 0 - Investor Newswire (NASDAQ:TCON)
www.investornewswire.com - December 2 at 3:18 PM
News IconTRACON Pharmaceuticals, Inc. (TCON) Under Analyst Spotlight - UK Market News (NASDAQ:TCON)
www.ukmarketnews.co.uk - December 2 at 3:18 PM
finance.yahoo.com logoTRACON Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (NASDAQ:TCON)
finance.yahoo.com - November 30 at 10:25 AM
News IconRSI Review on Shares of Tracon Pharmaceuticals Inc. (TCON) - Yankee Analysts (NASDAQ:TCON)
yankeeanalysts.com - November 29 at 3:44 PM
News IconTechnical Watch on These Shares: Tracon Pharmaceuticals Inc. (TCON) - StockTalk Daily (NASDAQ:TCON)
stocktalkdaily.com - November 26 at 5:34 PM
streetinsider.com logoTRACON Pharmaceutical (TCON) Prices 2.625M Share Common Stock Offering for Proceeds of ~$15.1M - StreetInsider.com (NASDAQ:TCON)
www.streetinsider.com - November 25 at 8:50 AM
marketexclusive.com logoTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Other Events - Market Exclusive (NASDAQ:TCON)
marketexclusive.com - November 25 at 8:50 AM
News IconTRACON Pharmaceuticals, Inc. TCON Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:TCON)
www.bioportfolio.com - November 24 at 11:09 AM
publicnow.com logoTRACON Pharmaceuticals Announces Pricing of Public Offering of Common Stock (NASDAQ:TCON)
www.publicnow.com - November 23 at 11:06 AM

Social

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Where is TRACON Pharmaceuticals' stock going? Where will TRACON Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 1-year price objectives for TRACON Pharmaceuticals' shares. Their predictions range from $10.00 to $15.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $13.00 in the next twelve months.

When will TRACON Pharmaceuticals announce their earnings?

TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

Who owns TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (6.66%), Eventide Asset Management LLC (6.62%), Wall Street Associates (1.85%), Perceptive Advisors LLC (0.77%), Alyeska Investment Group L.P. (0.77%) and Renaissance Technologies LLC (0.31%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, H Casey Logan, Jafco Super V3 Investment Limi, Peter W Sonsini and Ronald L Shazer.

Who sold TRACON Pharmaceuticals stock? Who is selling TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sii Investments Inc. WI.

Who bought TRACON Pharmaceuticals stock? Who is buying TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Eventide Asset Management LLC, Perceptive Advisors LLC, Alyeska Investment Group L.P. and Renaissance Technologies LLC.

How do I buy TRACON Pharmaceuticals stock?

Shares of TRACON Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TRACON Pharmaceuticals stock cost?

One share of TRACON Pharmaceuticals stock can currently be purchased for approximately $3.90.

TRACON Pharmaceuticals (NASDAQ:TCON) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Earnings History Chart

Earnings by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Dividend History Chart

Dividend Payments by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Last Updated on 2/25/2017 by MarketBeat.com Staff